Clinical Trials Logo

Invasive Pulmonary Aspergillosis clinical trials

View clinical trials related to Invasive Pulmonary Aspergillosis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05671328 Not yet recruiting - Clinical trials for Ventilator Associated Pneumonia

Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia

ASPIC
Start date: March 2023
Phase:
Study type: Observational

Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the causes of VAP. The hypothesis of the study is that the incidence of IPA is 12.4%. For each patient presenting with a suspicion of VAP and requiring a bronchoalveolar lavage (BAL), the diagnosis of API will be evaluated by biological examinations performed on blood and BAL. Medical and surgical history as well as clinical and biological data will be collected for 28 days or until discharge from the ICU.

NCT ID: NCT04848831 Not yet recruiting - Clinical trials for Invasive Pulmonary Aspergillosis

Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid

DipA2
Start date: June 1, 2021
Phase:
Study type: Observational

The aim of this research project is to compare the results of Aspergillus specific test methods Aspergillus Galactomannan Enzyme Immunoassay (GM-EIA), Aspergillus polymerase chain reaction (PCR), Aspergillus Galactomannan Lateral Flow Assay (LFA) from different respiratory tract secretions. The bronchoalveolar lavage (BAL) fluid and bronchial secretions (NBL) are compared in the same examination for each patient.

NCT ID: NCT02234739 Not yet recruiting - COPD Clinical Trials

Voriconazole for IPA in Chinese Patients With COPD

VIA-COPD
Start date: October 2014
Phase: Phase 4
Study type: Interventional

voriconazole is recommended as first-line therapy for invasive pulmonary aspergillosis, however the efficacy and safety of voriconazole for treating invasive pulmonary aspergillosis secondary to COPD is not clear. This study aims to investigate the effectiveness and tolerability of intravenous voriconazole for treatment of invasive pulmonary aspergillosis in Chinese patients with COPD, by monitoring changes in clinical symptoms, eradication of aspergillus, improvement of chest imaging as well as record of possible adverse reactions following 2-week intravenous instillation of voriconazole.

NCT ID: NCT02100761 Not yet recruiting - Clinical trials for Invasive Pulmonary Aspergillosis

CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients

Start date: June 2014
Phase: N/A
Study type: Observational

To investigate the relationship between cytochrome P450 (CYP) 2C19 genetic polymorphism and the steady-state blood concentration of voriconazole in Chinese patients with invasive pulmonary aspergillosis (IPA), and to assess the effects of voriconazole trough concentration on the prognosis of IPA patients.